This was not the original topic for today’s scheduled column, but over the course of the last 24 hours between Damjan’s column yesterday on the Lin v. Siemens case and its impact on FCPA issues specific to healthcare companies in China, a client conversation, and an email forwarded to me by a friend in China [...]

For life science companies building and executing a market access strategy in China, the question is rarely whether or not a big enough market exists to justify their efforts; rather, the most pressing question is what they will have to trade in order to open the market itself.  The question of what the exchange is [...]

As 2012 draws to a close, the two most impactful reforms China has set in motion within the healthcare space are the ongoing expansion of the country’s insurance plan and attempts to reform its hospitals.  The latter is one of the more complex and multi-faceted aspects of China’s overarching objectives as part of its 2009 [...]